抗II型胶原抗体与急性起病类风湿关节炎表型相关并预示5年随访炎症程度较低
该研究在773例瑞典类风湿关节炎(RA)患者中检测基线抗II型胶原(anti-CII)抗体和抗CCP2抗体,并随访5年临床数据及HLA-DRB1*等位基因。结果显示anti-CII阳性与诊断时及6个月内炎症指标升高相关,但随时间改善,且更常达到EULAR良好或中等反应;anti-CCP2则与6个月后关节肿胀和DAS28恶化相关。anti-CII与HLA-DRB1*01和*03正相关,吸烟者anti-CII水平较低。
要点
- anti-CII阳性RA表现为早期炎症活跃但5年内炎症改善的急性起病表型。
- anti-CII与HLA-DRB1*01和*03正相关,双阳性者anti-CII水平显著更高。
- anti-CII阳性患者更常达到EULAR良好或中等反应,但抗体检测不用于诊断。
核心结论
- anti-CII血清阳性RA代表一种独特表型,早期anti-CII检测可预测较好的炎症结局。
研究设计与样本
- 基于瑞典EIRA研究的773例RA患者,基线检测anti-CII和anti-CCP2,其中1476例有HLA-DRB1*信息,随访5年临床数据来自SRQ登记。
主要发现
- anti-CII与诊断时及6个月内的CRP、ESR、SJC、DAS28和DAS28CRP升高相关。
- anti-CCP2与6个月至5年的SJC和DAS28相关,但早期不相关。
- anti-CII与CRP、ESR、SJC、TJC和DAS28的改善相关,而anti-CCP2与SJC和DAS28随时间恶化相关。
- anti-CII阳性患者更常达到EULAR良好或中等反应。
- anti-CII与HLA-DRB1*01和*03正相关且有显著交互作用,双阳性个体平均anti-CII水平比HLA双阴性者高14倍以上;吸烟者anti-CII水平较低。
关键数值与推荐
- anti-CII阳性与诊断时及6个月内CRP、ESR、SJC、DAS28和DAS28CRP升高相关。
- anti-CCP2与6个月至5年的SJC和DAS28相关。
- anti-CII阳性患者达到EULAR良好或中等反应的比例高于阴性患者。
- HLA-DRB1*01和*03双阳性个体平均anti-CII水平比HLA双阴性者高14倍以上。
临床怎么用
- 早期检测anti-CII有助于识别预后较好、炎症可能自行改善的RA亚型。
- anti-CII阳性RA患者可能更易达到EULAR良好或中等反应。
- anti-CII不用于RA诊断,但可作为预后参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antifibrillar collagen type II (anti-CII) antibody-positive patients with rheumatoid arthritis (RA) have early but not late signs of increased inflammation and joint erosions. We wanted to replicate this in a large RA cohort, and to relate to human leukocyte antigen (HLA)-DRB1* alleles. METHODS: Anti-CII and anti-cyclic citrullinated peptide (CCP)2 were measured at baseline in 773 patients with RA from the Swedish Epidemiological Investigation in Rheumatoid Arthritis (EIRA) study with clinical follow-up data from the Swedish Rheumatology Quality Register (SRQ) registry, and 1476 with HLA-DRB1* information. Comparisons were done concerning C reactive protein (CRP), erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), Disease Activity Score encompassing 28 joints based on ESR (DAS28), DAS28CRP, pain-Visual Analogue Scale (VAS), global-VAS and Health Assessment Questionnaire Score (HAQ) at eight occasions during 5 years, and association with HLA-DRB1* alleles. RESULTS: Anti-CII associated with elevated CRP, ESR, SJC, DAS28 and DAS28CRP at diagnosis and up to 6 months, whereas anti-CCP2 associated with SJC and DAS28 from 6 months to 5 years, but not earlier. The anti-CII-associated phenotype was strong, and predominated in anti-CII/anti-CCP2 double-positive patients. Anti-CII was associated with improvements in CRP, ESR, SJC, TJC and DAS28, whereas anti-CCP2 was associated with deteriorations in SJC and DAS28 over time. Anti-CII-positive patients achieved European League Against Rheumatism good or moderate response more often than negative patients. Anti-CII was positively associated with HLA-DRB1*01 and HLA-DRB1*03, with significant interaction, and double-positive individuals had >14 times higher mean anti-CII levels than HLA double negatives. Whereas smoking was associated with elevated anti-CCP2 levels, smokers had lower anti-CII levels. CONCLUSIONS: Anti-CII seropositive RA represents a distinct phenotype, in many respects representing the converse to the clinical, genetic and smoking associations described for anticitrullinated protein peptide autoantibodies. Although not diagnostically useful, early anti-CII determinations predict favourable inflammatory outcome in RA.
引用
- Manivel VA, Mullazehi M, Padyukov L, et al. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up. Ann Rheum Dis. 2017. PMID: 28336519. doi:10.1136/annrheumdis-2016-210873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。